Tesamorelin is a peptide bioregulator that is a synthetic analog of the hormone releasing growth hormone (GHRH). It stimulates the physiological production of its own growth hormone through the pituitary gland, without directly interfering with the hormonal balance. Tesamorelin is the only GHRH-class peptide officially approved by the FDA, with an extensive clinical base and proven efficacy, primarily in reducing visceral fat and improving metabolic health.
Tesamorelin is a synthetic analogue of the hormone releasing growth hormone, consisting of 44 amino acids. Structurally, it is based on the sequence of human GHRH and additionally contains a trans-3-hexenoyl group on the N-terminal tyrosine residue, which increases the stability of the compound. In the research and pharmacological context, tesamorelin is studied in connection with the regulation of growth hormone secretion and IGF-https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000ChemR.pdf?utm_source=chatgpt.com
General information
| Features | Values |
|---|---|
| The peptide sequence | trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 |
| The molecular formula | C221H366N72O67S |
| Molecular weight | 5136.0 g/mol |
| CAS Number | 218949-48-5 |
| PubChem CID | 16137828 |
| Synonyms | Tesamorelin, Tesamorelin acetate, TH9507, Egrifta |
Lyophilized peptides
All peptides undergo lyophilization, a process that is necessary to extend their shelf life, as well as preserve the purity and integrity of the peptides during storage and transportation. Product Usage: This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
Product Usage
This product is intended solely for research purposes. All product information provided on this website is intended for educational purposes.
The purity of peptides is more than 99%
Confirmed by certified laboratories. The analysis certificates are available before purchase.
GMR Production Standards
Manufactured in enterprises in accordance with good manufacturing practices. Complete documentation on tracking the origin of the product.
Execution of orders at the highest level
Sending orders the next day at checkout before 12:00 Moscow time. Free standard shipping across the country for orders starting from 15,000₽ (or equivalent).
Without fillers and additives
Only pure active connections. The composition is confirmed by experts for reliable in vitro studies.
Tesamorelin is a synthetic analog of growth hormone releasing hormone created to stimulate endogenous GH secretion and increase IGF-1 levels. It is a 44-amino acid peptide modified for greater resistance to enzymatic degradation compared to natural GHRH. The most studied area of its application is associated with HIV-associated accumulation of visceral fat, and in the USA tesamorelin has been registered specifically to reduce excess abdominal visceral fat in adults with HIV lipodystrophy. The current FDA instructions for EGRIFTA WR indicate that the average half-life after subcutaneous administration is about 11 minutes, while the biological effect is realized through stimulation of its own somatotropic axis, and not through the administration of exogenous growth hormone. label
Stimulation of growth hormone and IGF-1
The main research area of tesamorelin is related to the activation of the GHRH receptor in the pituitary gland, increased pulse secretion of growth hormone and a subsequent increase in IGF-1. It is due to this mechanism that the molecule is considered as a tool for studying metabolic regulation, body composition, and changes in visceral fat. In early clinical studies in patients with HIV-associated lipodystrophy, the use of GHRH analog was accompanied by an increase in IGF-1, an increase in fat-free weight and a decrease in visceral fat, which became the basis for further study of tesamorelin. Growth Hormone–Releasing Hormone in HIV-Infected Men With Lipodystrophy: A Randomized Controlled Trial | Allergy and Clinical Immunology | JAMA | JAMA Network
Visceral fat and body composition
Tesamorelin is best known for its research in reducing visceral adipose tissue. In a study published in NEJM, daily use of tesamorelin for 26 weeks in HIV patients resulted in a reduction in visceral fat and an improvement in some lipid parameters. More recent reviews and clinical reviews also emphasize that tesamorelin's effect is primarily directed at visceral rather than subcutaneous adipose tissue, which determines its research value in models of abdominal obesity in this group of patients. Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV | New England Journal of Medicine
Liver and ectopic fat accumulation
A separate important area of tesamorelin research is related to fatty liver disease in HIV patients. In a randomized clinical trial, JAMA tesamorelin reduced not only visceral fat, but also liver fat in HIV-infected patients with abdominal fat accumulation. Subsequent studies and reviews noted that the year of therapy was accompanied by a relative decrease in liver fat by about 37 percent and a slowdown in the progression of fibrosis, which made tesamorelin one of the most interesting molecules for studying the relationship of the GH/IGF-1 axis with NAFLD in the context of HIV. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial - PubMed
Immunometabolic and inflammatory effects
In addition to its effect on fat, tesamorelin is being investigated in the context of systemic inflammation and immunometabolic disorders. Clinical and review publications have described that a decrease in visceral adipose tissue on the background of tesamorelin was accompanied by a favorable dynamics of individual inflammatory markers. This supports interest in the peptide as a research tool to study the relationship between visceral obesity, chronic inflammation, and metabolic complications in HIV patients. Effects of Tesamorelin on Inflammatory Markers in HIV Patients with Excess Abdominal Fat: Relationship with Visceral Adipose Reduction - PMC
Neurocognitive direction
Tesamorelin has also been studied in a neurocognitive context, as abdominal obesity, inflammation, and decreased IGF-1 are considered possible factors of cognitive impairment in HIV. However, this direction is still less certain. In 2024-2025, it was reported that tesamorelin reduced abdominal obesity and increased IGF-1, but no convincing improvement in cognitive performance was shown at intermediate stages. Therefore, it is more correct for the site to indicate this as a promising, but not yet clinically confirmed research area. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity - PubMed
Pharmacokinetics and research value
From the point of view of pharmacology, tesamorelin is interesting because, with a short half-life, it triggers a physiologically significant endogenous hormonal reaction. This distinguishes it from direct GH administration and makes it convenient for studying pulse stimulation of the somatotropic axis. The FDA documents and the clinical and pharmacological review note that the molecule retains affinity for GHRH receptors, has increased stability compared to natural GHRH, and is used as a GHRH analog rather than as a substitute for growth hormone itself. label
Links